The Preclinical Imaging Market Size was valued at USD 4.18 billion in 2023 and is expected to reach USD 6.31 billion by 2032 and grow at a CAGR of 4.69% over the forecast period 2024-2032. This report identifies trends in imaging modalities and the expanding use of novel technologies, fostering innovation in biomedical research and drug development. It analyzes growing funding for research and development, combined with rising health care and research expenditure in various regions, in shaping market growth. It further discusses emerging innovations like AI-assisted and multimodal imaging systems, advancing accuracy and effectiveness. The report also examines regulatory and compliance trends, focusing on their influence on product approvals, standardization, and market entry strategies.
To Get more information on Preclinical Imaging Market - Request Free Sample Report
Drivers
The preclinical imaging market is primarily driven by the increasing demand for drug discovery and development, alongside advancements in imaging technologies.
As the incidence of chronic diseases like cancer and neurological conditions increases, the demand for accurate and non-surgical imaging modalities to facilitate research is increasing. The biotechnology and pharmaceutical sectors are making significant investments in preclinical research, driving the market. The Pharmaceutical Research and Manufacturers of America (PhRMA) reported that biopharmaceutical firms spent more than USD 100 billion on R&D in recent years. Technological innovations, such as multimodal imaging, high-resolution MRI, and artificial intelligence-driven image analysis, are increasingly making preclinical imaging more efficient. Moreover, government grants and academic partnerships are strongly increasing research activity. For example, the National Institutes of Health (NIH) provides billions of dollars each year for research in medical imaging. Additionally, the growing use of molecular imaging modalities for targeted medicine and early disease diagnosis is fueling the market growth. The increasing application of preclinical imaging in oncology and neurology studies, coupled with the introduction of portable and affordable imaging systems, is opening new growth opportunities. With rising demand for faster and more precise preclinical studies, the preclinical imaging market will witness tremendous growth in the years to come.
Restraints
The preclinical imaging market faces several constraints, including the high cost of imaging systems and maintenance.
Advanced imaging modalities such as PET/MRI and high-resolution CT require substantial investments, making them less accessible for small and mid-sized research institutions. For instance, a high-end preclinical MRI system can cost over USD 1 million, limiting its adoption. Additionally, strict regulatory requirements and lengthy approval processes for imaging agents hinder market expansion. The requirement to comply with bodies such as the FDA and EMA adds complexity to gaining approvals, slowing down innovation. Another significant constraint is the lack of trained professionals to run and analyze sophisticated imaging data. The highly advanced nature of multimodal imaging necessitates highly skilled personnel, and the lack of expertise in developing markets hinders adoption. Additionally, ethical issues regarding the use of animal models in preclinical research have generated more stringent regulations, confining the domain of preclinical imaging. The reliance on a reduced set of imaging agents also hampers the scope of available research solutions. These aspects combined raise impediments to the common use of preclinical imaging technologies, hindering the overall market growth even as demand for better imaging solutions in biomedical research increases.
Opportunities
The preclinical imaging market presents significant opportunities, particularly in the areas of AI-driven imaging, molecular imaging, and emerging applications in regenerative medicine.
Artificial intelligence (AI) integration in imaging solutions is transforming image analysis, making it possible to detect disease markers faster and more accurately. A report states that AI-based imaging can enhance diagnostic accuracy by 30-40%, opening up new avenues for automation in preclinical research. The growth of molecular imaging methods, including optical and photoacoustic imaging, is also creating new avenues for the visualization of cellular processes in real-time. Further, the increasing interest in personalized medicine is propelling demand for cutting-edge imaging technologies that can detect disease mechanisms in their early stages. Partnerships between pharmaceutical organizations and research institutes are also powering innovation, as new imaging biomarkers and contrast agents are developed. The rise of 3D imaging and hybrid imaging platforms is also providing new opportunities for cancer and neurological research. Another significant potential is in expanding preclinical imaging solutions to other non-traditional research applications, including nanomedicine and regenerative therapy. With constant improvements and R&D investment, the market for preclinical imaging has significant potential to make a difference in medical research and drug discovery.
Challenges
The complexity of multimodal imaging integration and limitations in imaging resolution.
One of the key challenges is the Seamless integration of various imaging modalities like PET, SPECT, and MRI into a single system. A combination of various imaging modalities increases data complexity and requires advanced computational tools for proper analysis. Another crucial challenge is the low penetration of preclinical imaging in developing countries because of high equipment prices and poor infrastructure. The developing regions usually do not have the right research facilities and expertise, which limits market development. There is also an emerging demand for advanced imaging agents that are more biocompatible and specific. Limited availability of present contrast agents and radiotracers impacts in-depth biological investigation. There is also a continuing challenge from concerns regarding animal welfare and growing regulatory pressure on ensuring the ethical use of animals in preclinical research. The emergence of alternative imaging models, for example, organ-on-chip technology, is likely to replace the demand for conventional preclinical imaging. Nevertheless, despite such challenges, current technological advancements and collaborative efforts between academia and industry stakeholders are anticipated to propel solutions, leading to the sustained expansion of the preclinical imaging market.
By Product
The optical imaging segment accounted for the highest revenue share of 11.9% in 2023 due to its extensive use in preclinical imaging, disease detection, and biomarker identification. The high-resolution, real-time imaging capability of optical imaging with minimal invasiveness has helped it lead the market.
The multimodal imaging segment is expected to see the most rapid growth because it can combine various imaging modalities to offer more extensive and precise diagnostic information. Its rapid growth is being driven by the growing use of hybrid imaging systems in preclinical research and clinical use.
By Application
The research & development segment led the market, holding the highest revenue share in 2023. This is because of the growing emphasis on biomedical research, heightened government investments, and widening applications of imaging methods in preclinical research and translational research. Increasing demand for sophisticated imaging solutions within academic and commercial research also establishes its leading position.
The drug discovery segment is poised to expand at the fastest rate, mainly because of the increasing use of imaging technologies in the biotech and pharmaceutical sectors. Growing demand for high-throughput screening, molecular imaging, and personalized medicine in drug development is driving demand for advanced imaging methods in this segment.
By End-Use
The pharma and biotech companies segment dominated the market with a 35.9% share in revenue in 2023, fueled by the growing applications of imaging technologies in drug discovery, preclinical research, and biomarker verification. The inclusion of imaging solutions in pharmaceutical workflows for precision medicine and clinical trials has been the major driver for its leadership.
The research institutes segment is likely to witness the most rapid growth, driven by increasing government investment and academic-sponsored research initiatives. The increased focus on translational research and advances in imaging technologies are also driving the usage of imaging solutions across research centers globally.
North America led the preclinical imaging market in 2023, with the highest revenue share of 28.3%. The region's lead is due to the presence of established pharmaceutical and biotechnology companies, high levels of research and development investments, and access to advanced imaging technology. The region also enjoys strong government support for biomedical research and collaboration between academia and industry stakeholders. Moreover, the growing incidence of chronic diseases and the increasing need for precision medicine have fueled the use of preclinical imaging solutions in different research applications. The availability of leading market players and ongoing technological advancements also support North America's dominance in the market.
The Asia-Pacific market is expected to have the fastest expansion shortly, fueled by growth in investments for health care infrastructure, rising pharmaceutical and biotechnology sectors, and increasing academic research activities. China, India, and Japan are facing the rising need for preclinical imaging technologies amid the growth in drug discovery activities and government investment in biomedical research. The area is also witnessing a growing number of clinical trials and collaborations among international imaging firms and local research centers. Therefore, Asia-Pacific is likely to become a prominent growth center in the international preclinical imaging market.
Get Customized Report as per Your Business Requirement - Enquiry Now
PerkinElmer, Inc. – IVIS Spectrum, Quantum GX2 microCT
MR Solutions – MRS PET/CT, MRS 7T MRI
Siemens A.G. – Inveon PET/SPECT/CT
General Electric (GE) – Triumph PET/SPECT/CT
Mediso Ltd. – nanoScan PET/MRI, nanoScan SPECT/CT
Molecubes – β-CUBE (PET), γ-CUBE (SPECT), X-CUBE (CT)
TriFoil Imaging – eXplore CT, Triumph II
FUJIFILM SonoSite – Vevo 3100 (High-Frequency Ultrasound)
MILabs B.V. – VECTor PET/SPECT/CT
Bruker Corporation – BioSpec MRI, Albira PET/SPECT/CT
Agilent Technologies – MRI and spectroscopy solutions for preclinical research
In Feb 2024, Bruker Corporation acquired Spectral Instruments Imaging LLC, a leading provider of preclinical in-vivo optical imaging systems. This acquisition enhances Bruker BioSpin’s Preclinical Imaging (PCI) division by expanding its portfolio and strengthening its capabilities in disease research.
In Sep 2023, Revvity, Inc. launched next-generation preclinical imaging technologies, including IVIS Spectrum 2, IVIS SpectrumCT 2, Quantum GX3 microCT, and Vega ultrasound system, enhancing in vivo and ex vivo imaging capabilities. These innovations, aimed at advancing disease research and drug development, were showcased at the World Molecular Imaging Congress (WMIC) 2023 in Prague.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 4.18 billion |
| Market Size by 2032 | USD 6.31 billion |
| CAGR | CAGR of 4.69% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product [CT Imaging, MRI Imaging, PET/SPECT Imaging, Multi-modal Imaging, Optical Imaging, Ultrasound Imaging, Photoacoustic Imaging, Reagents, Services] • By Application [Research and Development, Drug Discovery] • By End-Use [Pharma and Biotech Companies, Research Institutes] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | PerkinElmer, Inc., MR Solutions, Siemens A.G., General Electric (GE), Mediso Ltd., Molecubes, TriFoil Imaging, FUJIFILM SonoSite, MILabs B.V., Bruker Corporation, Agilent Technologies. |
Ans: The Preclinical Imaging market is anticipated to grow at a CAGR of 4.69% from 2024 to 2032.
Ans: The market is expected to reach USD 6.31 billion by 2032, increasing from USD 4.18 billion in 2023.
Ans: The preclinical imaging market is primarily driven by the increasing demand for drug discovery and development, alongside advancements in imaging technologies.
Ans: The preclinical imaging market faces several constraints, including the high cost of imaging systems and maintenance.
Ans: North America dominated the Preclinical Imaging market.
Table of content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research & Academic Institutes Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research & Academic Institutes Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Trends in Imaging Modalities and Technology Adoption (2023-2032)
5.2 Research & Development Funding and Investments (2023)
5.3 Healthcare and Research Spending, by Region (2023)
5.4 Emerging Technologies and Innovations (2023-2032)
5.5 Regulatory and Compliance Trends (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and Promotional Activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Preclinical Imaging Market Segmentation, by Product
7.1 Chapter Overview
7.2 CT Imaging
7.2.1 CT Imaging Market Trends Analysis (2020-2032)
7.2.2 CT Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 MRI Imaging
7.3.1 MRI Imaging Market Trends Analysis (2020-2032)
7.3.2 MRI Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 PET/SPECT Imaging
7.4.1 PET/SPECT Imaging Market Trends Analysis (2020-2032)
7.4.2 PET/SPECT Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Multi-modal Imaging
7.5.1 Multi-modal Imaging Market Trends Analysis (2020-2032)
7.5.2 Multi-modal Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Optical Imaging
7.6.1 Optical Imaging Market Trends Analysis (2020-2032)
7.6.2 Optical Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Ultrasound Imaging
7.7.1 Ultrasound Imaging Market Trends Analysis (2020-2032)
7.7.2 Ultrasound Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.8 Photoacoustic Imaging
7.8.1 Photoacoustic Imaging Market Trends Analysis (2020-2032)
7.8.2 Photoacoustic Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.9 Reagents
7.9.1 Reagents Market Trends Analysis (2020-2032)
7.9.2 Reagents Market Size Estimates and Forecasts to 2032 (USD Billion)
7.10 Services
7.10.1 Services Market Trends Analysis (2020-2032)
7.10.2 Services Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Preclinical Imaging Market Segmentation, by Application
8.1 Chapter Overview
8.2 Research and Development
8.2.1 Research and Development Market Trends Analysis (2020-2032)
8.2.2 Research and Development Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Drug Discovery
8.3.1 Drug Discovery Market Trends Analysis (2020-2032)
8.3.2 Drug Discovery Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Preclinical Imaging Market Segmentation, by End-Use
9.1 Chapter Overview
9.2 Pharma and Biotech Companies
9.2.1 Pharma and Biotech Companies Market Trends Analysis (2020-2032)
9.2.2 Pharma and Biotech Companies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Research Institutes
9.3.1 Research Institutes Market Trends Analysis (2020-2032)
9.3.2 Research Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Preclinical Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.4 North America Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.5 North America Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.6.2 USA Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.6.3 USA Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.7.2 Canada Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.7.3 Canada Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.8.2 Mexico Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.8.3 Mexico Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Preclinical Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.6.2 Poland Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.6.3 Poland Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.7.2 Romania Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.7.3 Romania Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.9 turkey
10.3.1.9.1 Turkey Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Preclinical Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.4 Western Europe Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.5 Western Europe Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.6.2 Germany Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.6.3 Germany Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.7.2 France Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.7.3 France Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.8.2 UK Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.8.3 UK Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.9.2 Italy Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.9.3 Italy Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.10.2 Spain Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.10.3 Spain Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.13.2 Austria Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.13.3 Austria Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Preclinical Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.4 Asia Pacific Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.5 Asia Pacific Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.6.2 China Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.6.3 China Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.7.2 India Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.7.3 India Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.8.2 Japan Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.8.3 Japan Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.9.2 South Korea Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.9.3 South Korea Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.10.2 Vietnam Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.10.3 Vietnam Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.11.2 Singapore Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.11.3 Singapore Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.12.2 Australia Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.12.3 Australia Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Preclinical Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.4 Middle East Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.5 Middle East Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.6.2 UAE Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.6.3 UAE Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Preclinical Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.4 Africa Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.5 Africa Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Preclinical Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.4 Latin America Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.5 Latin America Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.6.2 Brazil Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.6.3 Brazil Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.7.2 Argentina Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.7.3 Argentina Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.8.2 Colombia Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.8.3 Colombia Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Preclinical Imaging Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Preclinical Imaging Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Preclinical Imaging Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
11. Company Profiles
11.1 PerkinElmer, Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product / Services Offered
11.1.4 SWOT Analysis
11.2 MR Solutions
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product / Services Offered
11.2.4 SWOT Analysis
11.3 Siemens A.G.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product / Services Offered
11.3.4 SWOT Analysis
11.4 General Electric (GE)
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product / Services Offered
11.4.4 SWOT Analysis
11.5 Mediso Ltd.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product / Services Offered
11.5.4 SWOT Analysis
11.6 Molecubes
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product / Services Offered
11.6.4 SWOT Analysis
11.7 TriFoil Imaging
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product / Services Offered
11.7.4 SWOT Analysis
11.8 FUJIFILM SonoSite
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product / Services Offered
11.8.4 SWOT Analysis
11.9 MILabs B.V.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product / Services Offered
11.9.4 SWOT Analysis
11.10 Bruker Corporation
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product / Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Product
CT Imaging
MRI Imaging
PET/SPECT Imaging
Multi-modal Imaging
Optical Imaging
Ultrasound Imaging
Photoacoustic Imaging
Reagents
Services
By Application
Research and Development
Drug Discovery
By End-Use
Pharma and Biotech Companies
Research Institutes
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Nucleic Acid Amplification Testing Market Size was valued at USD 7.36 Billion in 2023 and is expected to reach USD 20.62 Billion by 2032 and grow at a CAGR of 12.16% over the forecast period 2024-2032.
The 3D Printing Medical Device Software Market Size was valued at USD 0.07 billion in 2023 and is expected to reach USD 0.22 billion by 2031 and grow at a CAGR of 15.8% over the forecast period 2024-2031.
The Medical Coding Market, valued at USD 18.41 billion in 2023, is anticipated to achieve a valuation of USD 40.55 billion by 2032, experiencing a compound annual growth rate of 9.21% over the forecast from 2024 to 2032.
The Cardiac Safety Services Market Size was valued at USD 740 Million in 2023 and is expected to reach USD 1,888.34 Million by 2032 and grow at a CAGR of 11.48% over the forecast period 2024-2032.
The Immunomodulators Market size was USD 224.17 Billion in 2023 and is expected to Reach USD 391.78 Billion by 2032 and grow at a CAGR of 6.4% over the forecast period of 2024-2032.
The Leukapheresis Market valued at USD 192 Million in 2023, projected to reach USD 491.05 Million by 2032, growing at an 11.01% CAGR from 2024 to 2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
